• News
  • BioTech

Roche Agrees to Buy InterMune for $8.3 Billion for Lung Drug

Aug. 24 (Bloomberg) -- Roche Holding AG agreed to buy InterMune Inc. for about $8.3 billion in cash, gaining access to what may be the first drug in the U.S. for a lung disease that can be fatal within five years of diagnosis.

To continue reading, subscribe now
log in to your account
User Response
0 UserComments
Subscribe Today!